With 4.47 million shares changed hands, the volume of the stock remained lighter than its average volume of 7.51 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $0.6492 whereas the lowest price it dropped to was $0.5306. The 52-week range on BMRA shows that it touched its highest point at $1.35 and its lowest point at $0.24 during that stretch. It currently has a 1-year price target of $13.00. Beta for the stock currently stands at -1.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BMRA was up-trending over the past week, with a rise of 86.86%, but this was up by 90.48% over a month. Three-month performance surged to 76.99% while six-month performance rose 80.40%. The stock lost -34.07% in the past year, while it has gained 99.93% so far this year.
Float and Shares Shorts:
At present, 18.34 million BMRA shares are outstanding with a float of 16.17 million shares on hand for trading. On 2024-12-31, short shares totaled 0.36 million, which was 216.0 higher than short shares on 1732838400. In addition to Mr. Zackary S. Irani as the firm’s CEO & Director, Mr. Allen C. Barbieri serves as its Executive Vice-Chairman of the Board & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.12363 of BMRA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-08-31, BMRA reported revenue of $1636000.0 and operating income of -$993000.0. The EBITDA in the recently reported quarter was -$893000.0 and diluted EPS was -$0.06.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of $0.39 being high and $0.39 being low. For BMRA, this leads to a yearly average estimate of $0.39. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
